Misplaced Pages

Talaporfin: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 13:00, 18 August 2023 editOAbot (talk | contribs)Bots442,978 editsm Open access bot: doi updated in citation with #oabot.← Previous edit Latest revision as of 01:18, 11 February 2024 edit undoMaxim Masiutin (talk | contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers31,058 edits Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. Added s2cid. | Use this bot. | #UCB_Other 
Line 1: Line 1:
{{Short description|Chemical compound}} {{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
Line 53: Line 54:
'''Talaporfin''' (], also known as '''aspartyl chlorin''', mono-L-aspartyl chlorin e6, '''NPe6''', or '''LS11''') is a ] based ] used in ] (PDT). '''Talaporfin''' (], also known as '''aspartyl chlorin''', mono-L-aspartyl chlorin e6, '''NPe6''', or '''LS11''') is a ] based ] used in ] (PDT).


It absorbs red light at 664-667&nbsp;nm normally provided by a laser tuned to this wavelength.<ref name="pmid17409904">{{cite journal | vauthors = Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T | title = Photodynamic therapy (PDT) for lung cancers | journal = Journal of Thoracic Oncology| volume = 1 | issue = 5 | pages = 489–93 | date = June 2006 | pmid = 17409904 | doi = 10.1016/S1556-0864(15)31616-6 | doi-access = }}</ref> It absorbs red light at 664-667&nbsp;nm normally provided by a laser tuned to this wavelength.<ref name="pmid17409904">{{cite journal | vauthors = Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T | title = Photodynamic therapy (PDT) for lung cancers | journal = Journal of Thoracic Oncology| volume = 1 | issue = 5 | pages = 489–93 | date = June 2006 | pmid = 17409904 | doi = 10.1016/S1556-0864(15)31616-6 | doi-access = | s2cid = 19722977 }}</ref>


It was approved in Japan (in 2004) for ] of lung cancer and marketed as '''Laserphyrin'''.<ref>{{cite journal | vauthors = Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, Hirata T, Ohira T, Tsuboi M, Hirano T | title = Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer. | journal = Journal of Clinical Oncology | date = June 2006 | volume = 24 | issue = 18 suppl | pages = 7229 | doi = 10.1200/jco.2006.24.18_suppl.7229 | url = http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 }}</ref> It was approved in Japan (in 2004) for ] of lung cancer and marketed as '''Laserphyrin'''.<ref>{{cite journal | vauthors = Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, Hirata T, Ohira T, Tsuboi M, Hirano T | title = Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer. | journal = Journal of Clinical Oncology | date = June 2006 | volume = 24 | issue = 18 suppl | pages = 7229 | doi = 10.1200/jco.2006.24.18_suppl.7229 | url = http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 }}</ref>

Latest revision as of 01:18, 11 February 2024

Chemical compound

Pharmaceutical compound
Talaporfin
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		IV
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • N-{acetyl}-L-aspartic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H41N5O9
Molar mass711.772 g·mol
3D model (JSmol)
SMILES
  • CCC1=C2C=C3C(=C(C(=N3)C(=C4((C(=N4)C=C5C(=C(C(=CC(=C1C)N2)N5)C=C)C)C)CCC(=O)O)CC(=O)N(CC(=O)O)C(=O)O)C(=O)O)C
InChI
  • InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1
  • Key:VSEIDZLLWQQJGK-WSUYNKMOSA-N
  (what is this?)  (verify)

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a chlorin based photosensitizer used in photodynamic therapy (PDT).

It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength.

It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.

References

  1. Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology. 1 (5): 489–93. doi:10.1016/S1556-0864(15)31616-6. PMID 17409904. S2CID 19722977.
  2. Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, Hirata T, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer". Journal of Clinical Oncology. 24 (18 suppl): 7229. doi:10.1200/jco.2006.24.18_suppl.7229.
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
SPs/MIs
(M phase)
Block microtubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped

Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells

Categories:
Talaporfin: Difference between revisions Add topic